Neumora Therapeutics, Inc.
490 Arsenal Way
Suite 200
Watertown
MA
02472
United States
10 articles about Neumora Therapeutics, Inc.
-
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
11/27/2023
Neumora Therapeutics, Inc. today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult participants.
-
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/1/2023
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced financial results for the third quarter ended September 30, 2023 and provided a general business update.
-
Neumora Therapeutics to Participate in Upcoming Conferences in November
10/30/2023
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November.
-
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
-
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
-
Neumora Therapeutics Announces Pricing of Initial Public Offering
9/14/2023
Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share.
-
Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
7/18/2023
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Henry Gosebruch as president and chief executive officer and a member of the Company’s board.
-
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
7/18/2023
Neumora Therapeutics, Inc. announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of major depressive disorder.
-
Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.